MedTrace Logo

Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

NCT01546532 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2020-12-19

No results posted yet for this study

Summary

This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with chronic heart failure. In addition safety and effects on renal function and biomarkers will be assessed.

Conditions

  • Chronic Heart Failure (CHF)

Interventions

DRUG

RLX030

RLX030 as intravenous infusion for 24 hours.

DRUG

Placebo

Intravenous infusion of Placebo over 24 hours

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States
  • Germany
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01546532 on ClinicalTrials.gov